|
시장보고서
상품코드
2077215
재조합 에리스로포이에틴 시장 : 약제 종류별, 용도별, 유통 채널별, 지역별Recombinant Erythropoietin Market, By Drug Type, By Application, By Distribution Channel, By Geography |
||||||
가격
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
재조합 에리스로포이에틴 시장은 2026년에 77억 달러 규모에 달할 것으로 추정되며, 2033년까지 96억 6,000만 달러에 달할 것으로 예상됩니다. 2026년부터 2033년까지 CAGR 3.3%로 성장할 것으로 전망됩니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도: | 2025년 | 2026년 시장 규모: | 77억 달러 |
| 과거 데이터 기간: | 2020-2024년 | 예측 기간: | 2026-2033년 |
| 2026년부터 2033년까지 예측 기간 CAGR: | 3.30% | 2033년 시장 규모 예측: | 96억 6,000만 달러 |
전 세계 재조합 에리스로포이에틴 시장은 에포에틴 알파, 에포에틴 베타, 달베포에틴 알파 등의 제제 유형으로 구성되어 있으며, 암, 혈액 질환, 신장질환 등의 적응증 분야에 활용되고 있습니다. 이러한 제품들은 병원 약국, 소매 약국, 온라인 약국 등의 분야에서 도입되어 효율성, 성능 및 신뢰성 향상에 기여하고 있습니다. 이러한 분야의 채용 확대와 지속적인 제품 혁신이 맞물려 시장 확대를 지속적으로 뒷받침하고 있습니다.
시장 역학:
주요 적용 분야의 수요 증가, 효율성과 성능에 대한 중요성 부각, 그리고 지속적인 제품 혁신이 전 세계 재조합 에리스로포이에틴 시장의 성장을 견인할 것으로 예상되는 주요 요인입니다. 병원 약국 및 소매 약국에서의 채용 확대와 첨단 솔루션에 대한 투자 증가가 시장 확대를 더욱 뒷받침하고 있습니다.
예를 들어, 의료 서비스 제공자들은 암 및 관련 분야에 맞춘 서비스를 점점 더 많이 개발하고 있습니다. 또한, 지속적인 연구 개발과 신기술의 통합을 통해 예측 기간 동안 시장 참여자들에게 새로운 성장 기회가 창출될 것으로 전망됩니다.
본 조사의 주요 특징:
- 본 조사에서는 다양한 부문의 잠재적 수익 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한, 본 조사에서는 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 그리고 주요 기업들이 채택하는 경쟁 전략에 관한 중요한 인사이트도 제공하고 있습니다.
- 본 조사에서는 기업 개요, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략 등의 지표를 바탕으로 전 세계 재조합 에리스로포이에틴 시장의 주요 기업 개요을 소개하고 있습니다.
- 이 보고서를 통해 얻은 인사이트를 바탕으로, 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 제품 유형 업그레이드, 시장 확대 및 마케팅 전략에 대해 정보에 입각한 의사결정을 내릴 수 있게 됩니다.
- 본 '세계 재조합 에리스로포이에틴 시장 보고서'는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입 기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자 여러분은 전 세계 재조합 에리스로포이에틴 시장 분석에 활용되는 다양한 전략 매트릭스를 활용함으로써 의사결정을 원활하게 진행할 수 있을 것입니다.
목차
제1장 조사 목적과 가정
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 재조합 에리스로포이에틴 시장 : 약물 유형별, 2021-2033년
제5장 재조합 에리스로포이에틴 시장 : 용도별, 2021-2033년
제6장 재조합 에리스로포이에틴 시장 : 유통 채널별, 2021-2033년
제7장 재조합 에리스로포이에틴 시장 : 지역별, 2021-2033년
제8장 경쟁 구도
제9장 섹션
KSM 26.07.07Recombinant Erythropoietin Market is estimated to be valued at USD 7.70 Bn in 2026 and is expected to reach USD 9.66 Bn by 2033, growing at a compound annual growth rate (CAGR) of 3.3% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 7.70 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 3.30% | 2033 Value Projection: | USD 9.66 Bn |
The global recombinant erythropoietin market comprises drug type categories such as Epoetin-alfa, Epoetin-beta, and Darbepoetin-alfa, serving applications including Cancer, Hematology, and Renal diseases. These offerings are adopted across Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies and other areas, where they support improved efficiency, performance, and reliability. Growing adoption across these segments, combined with ongoing product innovation, continues to support expansion of the market.
Market Dynamics:
Rising demand across key application areas, increasing emphasis on efficiency and performance, and continued product innovation are major factors expected to drive growth of the global recombinant erythropoietin market. Expanding adoption among Hospital Pharmacies, and Retail Pharmacies and growing investment in advanced solutions are further supporting market expansion.
For instance, providers are increasingly developing offerings tailored to Cancer and related applications. Moreover, ongoing research and development, along with the integration of new technologies, is expected to create new growth opportunities for market players over the forecast period.
Key features of the study:
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global recombinant erythropoietin market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Amgen Inc., Johnson & Johnson (Janssen Pharmaceuticals), Pfizer Inc., F. Hoffmann-La Roche AG, Novartis AG, Biocon Limited, LG Chem Ltd., Intas Pharmaceuticals Ltd., Dr. Reddy's Laboratories Ltd., Celltrion Inc., 3SBio Inc., BioSidus SA, Astellas Pharma Inc, and Lotus Pharmaceutical Co, Ltd, among others.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global recombinant erythropoietin market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global recombinant erythropoietin market.
Detailed Segmentation:
- Global Recombinant Erythropoietin Market, By Drug Type (Revenue, USD Bn, 2021 - 2033)
- Epoetin-alfa
- Epoetin-beta
- Darbepoetin-alfa
- Others
- Global Recombinant Erythropoietin Market, By Application (Revenue, USD Bn, 2021 - 2033)
- Cancer
- Hematology
- Renal diseases
- Neurology
- Others
- Global Recombinant Erythropoietin Market, By Distribution Channel (Revenue, USD Bn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Company Profiles:
- Amgen Inc.*
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Johnson & Johnson (Janssen Pharmaceuticals)
- Pfizer Inc.
- F. Hoffmann-La Roche AG
- Novartis AG
- Biocon Limited
- LG Chem Ltd.
- Intas Pharmaceuticals Ltd.
- Dr. Reddy's Laboratories Ltd.
- Celltrion Inc.
- 3SBio Inc.
- BioSidus SA
- Astellas Pharma Inc
- Lotus Pharmaceutical Co, Ltd
"*" marked represents similar segmentation in other categories in the respective section.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Recombinant Erythropoietin, By Drug Type
- Market Recombinant Erythropoietin, By Application
- Market Recombinant Erythropoietin, By Distribution Channel
- Market Recombinant Erythropoietin, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Rising prevalence of chronic kidney disease (ckd)
- Restraints
- Stringent Regulatory Requirements
- Opportunities
- Emerging Markets
- Drivers
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product launch/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
4. Recombinant Erythropoietin Market , By Drug Type, 2021 - 2033, (US$ billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Epoetin-alfa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ billion)
- Epoetin-beta
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ billion)
- Darbepoetin-alfa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ billion)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ billion)
5. Recombinant Erythropoietin Market, By Application, 2021 - 2033, (US$ billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ billion)
- Hematology
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ billion)
- Renal diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ billion)
- Neurology
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ billion)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ billion)
6. Recombinant Erythropoietin Market, By Distribution Channel, 2021 - 2033, (US$ billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ billion)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ billion)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ billion)
7. Recombinant Erythropoietin Market, By Region, 2021 - 2033, (US$ billion)
- Introduction
- Market Share Analysis, By Country, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Country 2022-2033
- Country Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033,(US$ billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application , 2021 - 2033,(US$ billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ billion)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 - 2033, (US$ Bn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033,(US$ billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application , 2021 - 2033,(US$ billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ billion)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 - 2033, (US$ Bn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033,(US$ billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application , 2021 - 2033,(US$ billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ billion)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 - 2033, (US$ Bn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033,(US$ billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application , 2021 - 2033,(US$ billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ billion)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 - 2033, (US$ Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033,(US$ billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application , 2021 - 2033,(US$ billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ billion)
- 2021 - 2033, (US$ Bn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033,(US$ billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application , 2021 - 2033,(US$ billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ billion)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country/Region, 2021 - 2033, (US$ Bn)
- North Africa
- Central Africa
- South Africa
8. Competitive Landscape
- Amgen Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Johnson & Johnson (Janssen Pharmaceuticals)
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- F. Hoffmann-La Roche AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Biocon Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- LG Chem Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Intas Pharmaceuticals Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Dr. Reddy's Laboratories Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Celltrion Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- 3SBio Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- BioSidus SA
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Astellas Pharma Inc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Lotus Pharmaceutical Co., Ltd
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Analyst Views
9. Section
- Research Methodology
- About us
